NCIC Clinical Trials Group

Members / Participants Membership Information Clinical Trials Meetings
&
Education
Publications

Lectures
Correlative Science / Tumour Bank Notices Fellowships Committees Papaya Mango EDC BARL

2014

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

18 Dec 2014

General

Happy Holidays and Happy New Year!!!
The Canadian Cancer Trials Group's Central Operations and Statistics Office wishes everyone a very Merry Christmas, Happy Holidays, and Happy New Year.

Read more ....

'

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed with limited staff over the holidays. Web-based applications (i.e. MANGO, GCP) will be available. Please see the Canadian Cancer Trials Group website ... http://www.ctg.queensu.ca/public/notices/Cooperative_group_holiday_hours_2014.pdf.

Read more ....

'

Group Administrators Office

Single-Study Centres and DSMC Summary Reports
Trial-specific Data Safety Monitoring Committee Summary Reports are now posted on trial-specific websites.

Read more ....

'

Canadian Cancer Trials Group Recognition Awards
Canadian Cancer Trials Group's Central Operations and Statistics Office is seeking nominations for the 2015 Canadian Cancer Trials Group Recognition Awards honouring individuals and teams who have contributed significantly to the mission and activities of the Group.

Read more ....

'

Canadian Cancer Trials Group Bulletin in 2015
The first Bulletin of 2015 will be sent on Friday, January 16.

Read more ....

'

Canadian Cancer Trials Group Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2015 Annual Spring Meeting of Participants will be held May 1-3, 2015 at the Eaton Chelsea Hotel in Toronto.

Read more ....

'

Recent Publications
There were two recent publications, including the primary results of Canadian Cancer Trials Group MAC.4 / IBCSG 24-02 (SOFT) in the New England Journal of Medicine. These results were also just presented in San Antonio. Dr. Barbara Walley is the Canadian study chair.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group SC.23 - A Randomized Phase III Double Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases - was closed to accrual December 12, 2014.

Read more ....

'

Trial Activation
We are very excited to announce the activation of Canadian Cancer Trials Group/C17 SRC.6 (COG ARST1321)

Read more ....

'

Changes to the EDC Account Activation Process
The Canadian Cancer Trials Group Electronic Data Capture (EDC) account activation process has changed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

14 Nov 2014

General

Recent Publications
There were two recent publications - a quality of life and function analysis of Canadian Cancer Trials Group SC.20 and the other reporting aromatase inhibitor-associated bone fractures in Canadian Cancer Trials Group MA.27.

Read more ....

'

Group Administrators Office

7 Days in May Contributes $41,500 to Canadian Cancer Trials Group
The Canadian Cancer Trials Group is extremely grateful to the 7 Days in May Foundation who, for the second year in a row, is donating the proceeds of its seven-day ride around Lake Ontario to the Canadian Cancer Trials Group.

Read more ....

'

Canadian Cancer Trials Group BR.31 - Lung Cancer Trial Aimed at Curing NSCLC
The Canadian Cancer Trials Group has developed and is leading an international clinical trial of a new class of cancer drug aimed at curing non-small cell lung cancer (NSCLC) in patients who have had surgery and chemotherapy for disease confined to the lung.

Read more ....

'

Trial Management Group

RIPPLE - Next Wave of Trials Moving into RIPPLE
On December 11, 2014, the next round of trials will be moving into RIPPLE, Canadian Cancer Trials Group's Roster Interface Program and Participants List Environment. Please "read more" to view the list of trials.

Read more ....

'

CRA Volunteers Needed for CRA Executive Committee
The Clinical Research Associates Executive Committee is actively seeking CRA representatives for the Canadian Cancer Trials Group CRA Executive Committee.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group LY.16/LYSARC Relevance (RV-FOL-GELARC-0683) study was closed to accrual on November 10, 2014.

Read more ....

'

Permanent Closure of Intergroup-Led Trials
The following Intergroup-led trials have now been permanently closed -- ALC.1 (SWOG 0106), MAC.6 (IBCSG 26-02), PA.2 (ESPAC-3) and SR.5 (EORTC 62012).

Read more ....

'

Trial Activation
Canadian Cancer Trials Group IND.214 was recently centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 Oct 2014

General

Recent Publications
There were three recent publications, including one reporting the final analysis of NCIC CTB BR.26, one reporting results of the salvage portion of Canadian Cancer Trials Group LY.12, and the other related to Canadian Cancer Trials Group MY.10.

Read more ....

'

Trial Management Group

CRA Volunteer Needed for Sarcoma Site Executive Committee
Canadian Cancer Trials Group is actively seeking a CRA representative to sit on the Sarcoma Disease Site Committee Executive. If you are a CRA working on Canadian Cancer Trials Group trials in sarcoma/oncology, we encourage you to consider volunteering.

Read more ....

'

CRA Volunteers Needed for CRA Executive Committee
The Clinical Research Associates Executive Committee is actively seeking CRA representatives for the Canadian Cancer Trials Group CRA Executive Committee (CRAEC).

Read more ....

'

Drug Accountability Logs
Although the NCI US recently announced a new version of the Investigational Agent Accountability Record for oral agents to be used on NCI-affiliated trials conducted in Canada, the NCI US has agreed to Canadian Cancer Trials Group continuing to use existing Logs.

Read more ....

'

RIPPLE - What Trials Are Next and When?
Newly-activated trials and other trials have now been moved into RIPPLE. Read more to see a listing of these trials.

Read more ....

'

RIPPLE - New Role - Participants List Delegate (PLD)
A new role in RIPPLE has been created -- the Participants List Delegate (PLD), which will permit Qualified Investigators to "delegate the delegation" of trials staff in RIPPLE.

Read more ....

'

RIPPLE - Trial-Specific Credentialing/Training Features
New features have been built into RIPPLE to accommodate trial-specific credentialing and training requirements for individuals being added to the trial PLs.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

19 Sep 2014

General

Canadian Cancer Trials Group Investigator Awarded ASTRO Gold Medal
Dr. Mary Gospodarowicz has been awarded the American Society for Radiation Oncology (ASTRO) Gold Medal -- the Society's highest honour!!

Read more ....

'

Upcoming International Meeting
The 13th International Congress on Targeted Anticancer Therapies -- TAT -- will be held in Paris, France on March 2-4, 2015.

Read more ....

'

Group Administrators Office

Recent Publications
There were two recent publications, including one reporting primary results of Canadian Cancer Trials Group BR.25 and another updating the conduct of Canadian Cancer Trials Group CO.21.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

25 Aug 2014

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Aug 2014

General

Recent Publication
There was one recent publication -- Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Read more ....

'

Group Administrators Office

Central Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Monday, September 1, 2014 for Labour Day. Regular business hours will resume on Tuesday, September 2 at 8:30 am EDT.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group MEC.3 / ECOG E1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma - is now closed to accrual.

Read more ....

'

Permanent Trial Closure
Canadian Cancer Trials Group BR.25 - A Phase II Study of Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT)For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC) - has been permanently closed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

08 Aug 2014

Group Administrators Office

New Investigator Clinical Trials Course
SAVE THE DATE!!! The next Canadian Cancer Trials Group New Investigator Clinical Trials Course is planned for August 12-14, 2015 at Queen's University in Kingston, Ontario. Course application forms are now available!!!

Read more ....

'

Stand Up to Cancer Canada
The Canadian Cancer Trials Group is working with the Ontario Institute for Cancer Research to raise awareness about the first-ever Stand Up to Cancer Canada initiative being broadcast on September 5 on all 4 Canadian English language broadcasters.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

25 Jul 2014

General

Recent Publication
There was one recent publication reporting trastuzumab-associated cardiac events on Canadian Cancer Trials Group MA.24 (BIG 1-01).

Read more ....

'

Group Administrators Office

Central Operations and Statistics Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics office will be closed on Monday, August 4, 2014 for the Civic Holiday. Regular business hours will resume on Tuesday, August 5 at 8:30 am EDT.

Read more ....

'

Trial Management Group

Pharmacist Network Steering Group Seeks Volunteers
The Pharmacist Network Steering Group is actively seeking representatives for the Steering Group (Eastern Rep - Atlantic Provinces) and for the Genitourinary and Lung Disease Site Committees.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

11 Jul 2014

Group Administrators Office

Dr. Judy-Anne Chapman Is Retiring!!
After many years with the Canadian Cancer Trials Group, we would like to announce that Dr. Judy-Anne Chapman has retired. Please click on "read more" for a personal message from Elizabeth Eisenhauer.

Read more ....

'

Recent Publications
There were 3 recent publications, including two reporting primary results -- Canadian Cancer Trials Group SR.5 (EORTC 62012); and Canadian Cancer Trials Group MAC.4 (IBCSG 24-02) and Canadian Cancer Trials Group MAC.5 (IBCSG 25-02) -- the SOFT and TEXT trials -- published in the New England Journal of Medicine.

Read more ....

'

Trial Management Group

CRA Volunteer Needed for Sarcoma Disease Site Executive!
The Clinical Research Associates (CRA) Executive Committee is actively seeking a CRA representative for the Canadian Cancer Trials Group Sarcoma Disease Site Executive Committee.

Read more ....

'

Permanent Trial Closure
Three Intergroup trials which have included Canadian Cancer Trials Group participation -- Canadian Cancer Trials Group CX.4 (GOG 0191), Canadian Cancer Trials Group LY.11 (S9704) and Canadian Cancer Trials Group BR.23 (S0220)-- have now been permanently closed and trial activity will now cease.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

27 Jun 2014

General

Recent Publication
This recent publication defines benchmarks for overall survival (OS) and progression free survival (PFS) in patients with metastatic pancreatic cancer.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Tuesday, July 1, 2014 for Canada Day. Regular business hours will resume on Wednesday, July 2 at 8:30 am EDT. The Office IS open regular hours on Monday, June 30.

Read more ....

'

Update on the Initiative to Streamline Clinical Trials (ISCT)
The ISCT Recommendations were finalized in February 2014 and can now be found using this link ... http://n2canada.ca/isct/.

Read more ....

'

Canadian Cancer Trials Group PR.3/MRC PR07 UK Investigators Win Prize
Investigators in the UK have been awarded a Medical Breakthrough Award from the Cardiff University Innovation Network for their leadership of Canadian Cancer Trials Group PR.3/MRC PR07.

Read more ....

'

Trial Management Group

CRA Volunteer Needed for Sarcoma Disease Site Executive!
The Clinical Research Associates (CRA) Executive Committee is actively seeking a CRA representative for the Canadian Cancer Trials Group Sarcoma Disease Site Executive Committee.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group MA.33/TROG 07.01 - A Randomized Phase III Study of Radiation Doses and Fractionation Schedules for Ductal Carcinoma in Situ of the Breast - was closed to accrual June 20, 2014 after reaching its accrual target.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Jun 2014

Group Administrators Office

Single-Study Centres and DSMC Summary Reports
Trial-specific Data Safety Monitoring Committee Summary Reports are now posted on trial-specific websites.

Read more ....

'

Canadian Cancer Trials Group Job Opportunities
The Canadian Cancer Trials Group statistical and operations office, based at the Queen's University Cancer Research Institute in Kingston, Ontario, is seeking Physicians trained in a cancer-related specialty to join our research group as Senior Investigators.

Read more ....

'

Spring Meeting 2014 Expense Claims
Just a reminder to please submit your expense claim by 30 June 2014 at the latest. We will not accept any expense claim forms after 30 June 2014. Any claims received after 30 June 2014 will not be processed and will be returned.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

30 May 2014

Group Administrators Office

Canadian Cancer Trials Group and ASCO 2014
A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation are being presented at the American Society of Clinical Oncology Annual Meeting in Chicago, May 30 - June 3, 2014.

Read more ....

'

Canadian Cancer Trials Group Fellows Receive ASCO Merit Awards
Congratulations to Drs Lesleigh Abbott and Maria Bonomi, Fellows at Canadian Cancer Trials Group's Central Operations and Statistics Office, who have both received 2014 ASCO Merit Awards.

Read more ....

'

Spring Meeting 2014 Expense Claims
If you received a full-funded invitation to the 2014 Spring Meeting of Participants, please read the following carefully.

Read more ....

'

Canadian Cancer Trials Group Has Received $15 Million from the US NCI
The Canadian Cancer Trials Group has been awarded $15 million in funding from the US National Cancer Institute to strengthen its work leading major cancer clinical trials in Canada.

Read more ....

'

Trial Management Group

RIPPLE - Frequently Asked Questions (FAQs) are here!
In order to assist sites with implementation of the RIPPLE system, an FAQs page has been created to answer many of the questions you may have.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

16 May 2014

Group Administrators Office

Recent Publications
There were two recent publications -- one reporting results of quality of life on Canadian Cancer Trials Group MAP.3 and the other a general article about RECIST.

Read more ....

'

Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Monday, May 19, 2014 to celebrate Victoria Day.

Read more ....

'

Trial Management Group

RIPPLE Reminder
Friday, May 16, 2014 is the deadline for accepting the final paper MA.32 Participant List Change Forms at the Canadian Cancer Trials Group Central Operations and Statistics Office. After this date, any paper MA.32 PLCFs that are submitted will be returned.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group IND.194 - A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma - was closed to accrual on May 6, 2014.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

02 May 2014

Group Administrators Office

Spring Meeting Saturday Highlights
Once again, we are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, May 3 from 4:30-6:30 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Ian Tannock.

Read more ....

'

General Information for Spring Meeting Participants
We wanted to provide all Spring Meeting Participants with some general information about registration, wireless internet, and Trial Reports.

Read more ....

'

Spring Meeting Friday Highlights
A reminder to all those at the Canadian Cancer Trials Group Spring Meeting in Toronto -- don't forget to attend the special events planned for Friday afternoon including a special plenary session, Recognition Awards Ceremony and reception.

Read more ....

'

REMINDER - Canadian Cancer Trials Group Central Office Hours of Operation Are Changing
On Monday May 12, 2014, the Canadian Cancer Trials Group Central Operations and Statistics Office hours of operation will change to 8:30 am - 5:00 pm for phone/reception, and 9:00 am - 5:00 pm (EDT) for manually-assisted registrations/randomizations.

Read more ....

'

Recent Publication
The primary publication for Canadian Cancer Trials Group PRC.2 (CALGB 90202) was recently published in the Journal of Clinical Oncology.

Read more ....

'

Trial Management Group

RIPPLE and Investigator Credentialing
Effective April 28, 2014, the Roster Interface Program & Participants List Environment (RIPPLE) system was implemented for all Canadian Canadian Cancer Trials Group member centres.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 Apr 2014

Group Administrators Office

Spring Meeting Friday Highlights
As Spring Meeting quickly approaches, we wanted to highlight some of the special activities that will be taking place on Friday, May 2 from 4:30-6:00 pm, including A Special Plenary and the Canadian Cancer Trials Group Recognition Awards Ceremony and Reception.

Read more ....

'

Spring Meeting Saturday Highlights
Once again, we are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, May 3 from 4:30-6:30 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Ian Tannock.

Read more ....

'

General Information for Spring Meeting Participants
In addition to highlighting Spring Meeting events on Friday and Saturday, we wanted to provide all Spring Meeting Participants with some general information about registration, wireless internet, and Spring Meeting Trial Reports.

Read more ....

'

Canadian Cancer Trials Group Central Ops and Stats Office Hours of Operation
On Monday May 12, 2014, the Canadian Cancer Trials Group Central Operations and Statistics Office hours of operation will change to 8:30 am - 5:00 pm for phone / reception, and 9:00 am - 5:00 pm (EDT) for manually-assisted registrations/randomizations.

Read more ....

'

Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Friday, April 18, 2014 in observance of Good Friday. Regular business hours will resume on Monday, April 21 at 8:00 am EDT.

Read more ....

'

Office of Compliance and Oversight

New Pharmacy Compliance Requirement/Updated CTMB Guidelines
New pharmacy compliance requirements pertaining to drug accountability and agent storage have recently been introduced by CTEP.

Read more ....

'

Trial Management Group

REMINDER -- RIPPLE and Investigator Credentialing
The RIPPLE roll-out date -- April 28, 2014 -- is fast approaching. There will be two final RIPPLE / updated policy training webinars -- Tuesday, April 22 and Thursday, April 24, both at 1 pm EDT. Please be sure to read the complete story ...

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Heartbleed vulnerability

Canadian Cancer Trials Group

URGENT from Canadian Cancer Trials Group Group Administrators Office -- HeartBleed Bug and Your Password

As explained in the email you received from us on Friday, April 11, 2014, we require ALL Canadian Cancer Trials Group participants to change their MEMBER PASSWORD used for accessing Canadian Cancer Trials Group web-based systems due to the widespread OpenSSL HeartBleed bug (http://www.cbc.ca/news/technology/heartbleed-web-security-bug-what-you-need-to-know-1.2603988).

The purpose of this email is to let you know that we have reset the password for all participants who have not yet been able to do so. In order to regain access to Canadian Cancer Trials Group systems requiring your member password, please visit the following link

https://scooby.ctg.queensu.ca/passwords/?go=main

and follow instructions entitled "Reset Member Password (Forgot Password)".

ABOUT YOUR MEMBER PASSWORD
The "member password" is used to access the Canadian Cancer Trials Group members-only website, Mango, and other web systems, but NOT EDC Medidata Rave.

ABOUT YOUR EDC PASSWORD
The EDC (Electronic Data Capture) password (not the member password) is used to access Medidata Rave. Although the EDC system was never vulnerable to the HeartBleed bug, you must change your EDC password if your EDC password is currently the SAME password used on other Canadian Cancer Trials Group systems OR any other system on the internet (e.g. GMail, Yahoo, etc.). Any of these sites could potentially have been compromised; thus, that password should be considered insecure.

To change your EDC password the link is https://edc.ctg.queensu.ca

If you have any technical issues changing your passwords, please see http://www.ctg.queensu.ca/help/

If you have any other questions, please contact Canadian Cancer Trials Group Bulletin


Heartbleed vulnerability

Canadian Cancer Trials Group

Heartbleed vulnerability

This note explains the Canadian Cancer Trials Group response to the HeartBleed SSL bug (http://www.cbc.ca/news/technology/heartbleed-web-security-bug-what-you-need-to-know-1.2603988), please note there are important actions required by you below.

On wide review of all IT systems at Canadian Cancer Trials Group, two systems were identified that used software that was vulnerable to HeartBleed. This did not include the clinical data or patient enrolment/randomization systems. All CTG systems have been patched and security keys and certificates have been updated. Canadian Cancer Trials Group systems are now updated and secure as of 2014-April-10.

MEMBER PASSWORD:
In order to follow conservative best practices, we now require all participants to change their MEMBER PASSWORD used for accessing Canadian Cancer Trials Group web based systems. The "member password" is used to access the Canadian Cancer Trials Group members only website, Mango, and other web systems but NOT EDC Medidata Rave.
Please reset your member password within the next 3 working days. At that point, if you have not changed your password, we will re-set your password and send you further instructions.

To change your member password the link is https://scooby.ctg.queensu.ca/passwords/?go=login&target=change_pw

EDC PASSWORD:
With respect to EDC (electronic Data Capture) - The "EDC password" (not the member password) is used to access Medidata Rave.
Although, the EDC system was never vulnerable to the heartbleed bug, you must change your EDC password if your EDC password is currently the SAME password used on other Canadian Cancer Trials Group systems OR any other system on the internet (e.g. GMail, Yahoo, etc.). Any of these sites could potentially have been compromised, thus that password should be considered insecure.

To change your EDC password the link is https://edc.ctg.queensu.ca

If you have any technical issues changing your passwords, please see http://www.ctg.queensu.ca/help/

If you have any other questions, please contact Heather Stanton Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

04 Apr 2014

General

GA.1 (TROG 0808) Featured in International Innovation
Canadian Cancer Trials Group GA.1 (TROG 0808), also known as TOPGEAR, has been featured in International Innovation, a global resource providing insight and analysis on current scientific research trends.

Read more ....

'

Group Administrators Office

Recent Publication
There was one recent publication reporting primary results of Canadian Cancer Trials Group MA.27B - The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer. A Companion Study to MA.27.

Read more ....

'

Reminder -- Canadian Cancer Trials Group Spring Meeting Event
We are very pleased to announce Dr. Ian Tannock as the 2014 "Cosbie Lecturer". The title of Dr. Tannock's talk is "Whither (or Wither?) the Randomised Clinical Trial?"

Read more ....

'

Canadian Cancer Trials Group Annual Spring Meeting Highlights
The Canadian Cancer Trials Group Annual Spring Meeting is scheduled for May 2-4, 2014 at the Eaton Chelsea Hotel in Toronto. We wanted to share some activities planned for the Spring Meeting.

Read more ....

'

Office of Compliance and Oversight

CTEP Update - Retirement of AdEERS
Please note, AdEERS has officially been retired and is no longer accessible as of April 1, 2014. CTEP-AERS has taken its place and is now REQUIRED for use in place of AdEERS for expedited SAE reporting for CTEP clinical trials.

Read more ....

'

Record Retention
The Office of Compliance and Oversight (OCO), in conjunction with the Trial Management Group (TMG), are pleased to announce that the date the records retention requirements are met is now available using the Canadian Cancer Trials Group Permanent Closure Search Utility.

Read more ....

'

Trial Management Group

RIPPLE... Training Sessions Are Coming Up
RIPPLE is being implemented on April 28 and Central Office will be holding training sessions for all Qualified Investigators and CRAs at Canadian member centres. Click "read more" for more information and for the schedule.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


SPECIAL Canadian Cancer Trials Group BULLETIN from Dr. E Eisenhauer - Dr. Janet Dancey appointed new Director of Canadian Cancer Trials Group effective Sept 1, 2014

Canadian Cancer Trials Group

SPECIAL Canadian Cancer Trials Group BULLETIN from Dr. E Eisenhauer - Dr. Janet Dancey appointed new Director of Canadian Cancer Trials Group effective Sept 1, 2014

Dear Members of Canadian Cancer Trials Group, Canadian Cancer Trials Group staff and colleagues;

With this note I am delighted to let you know that, following an international search, Queen's University and the Canadian Cancer Society announced today that Dr. Janet Dancey will be the New Director of Canadian Cancer Trials Group effective September 1, 2014

CCS Media release: http://www.newswire.ca/en/story/1334675/new-director-appointed-to-lead-the-ncic-clinical-trials-group

Queen's Media release: http://www.queensu.ca/news/articles/leading-way-critical-cancer-research-0

Please join me in congratulating Janet for this well-deserved honour! Most if not all of you know Janet - she is one of this country's most respected oncologists and known internationally in the field of cancer clinical trials. I know she will do a tremendous job in leading Canadian Cancer Trials Group to even greater heights in the years to come.

I would also like to thank the members of the Canadian Cancer Trials Group investigator community who served on the search committee which involved a rigorous international search.

Janet will also remain in her leadership role at OICR as Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN), which as many of you also know is now undergoing review of a comprehensive business case prior to rolling into the next phase of funding.

I will look forward to officially congratulating Janet at our Canadian Cancer Trials Group Spring meeting - May 2-4 in Toronto - where she will take the opportunity of that meeting to present her vision for the future of clinical trials in Canada and specifically the role of NCI CTG in that future at the plenary session on the Saturday.

Meanwhile, I will continue to enjoy the privilege of serving Canadian Cancer Trials Group as Interim Director until August 31, 2014 - when I will pass the torch with great confidence to Janet Dancey.

With best regards,

Elizabeth Eisenhauer MD FRCPC
Interim Director, Canadian Cancer Trials Group

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

21 Mar 2014

Group Administrators Office

2014 Spring Meeting Event -- Cosbie Lecture
We are very pleased to announce Dr. Ian Tannock as the 2014 "Cosbie Lecturer". The title of Dr. Tannock's talk is "Whither (or Wither?) the Randomised Clinical Trial?"

Read more ....

'

2014 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2014 Annual Spring Meeting of Participants will be held May 2-4, 2014 at the Eaton Chelsea Hotel in Toronto. A draft schedule is available.

Read more ....

'

Office of Compliance and Oversight

Remote Roster Administrator (RRA) Clarification
An item in the March 7 Bulletin announced a new requirement for each Canadian Cancer Trials Group member centre to assign personnel to the Remote Roster Administrator (RRA) role. Please note that the RRA role is required for Canadian centres only.

Read more ....

'

Trial Management Group

Permanent Trial Closures
Two Canadian Cancer Trials Group trials have been permanently closed -- Canadian Cancer Trials Group BL.8 (EORTC 30994) and Canadian Cancer Trials Group MA.21 -- and trial activity will now cease.

Read more ....

'

Trial Activation
Canadian Cancer Trials Group LYC.1 (ECOG E1411) - an Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma - was centrally activated on March 12, 2014.

Read more ....

'

Trial Closed to Activation
Canadian Cancer Trials Group GA.2 (AG0212OG) -- (INTEGRATE): A Randomized Phase II Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Esophago-Gastric Cancer -- was closed to accrual on February 25, 2014.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Mar 2014

General

RIPPLE? It's Coming!
The Roster Interface Program & Participants List Environment (RIPPLE), Canadian Cancer Trials Group's new electronic web-based system for Canadian Cancer Trials Group membership accounts and Participant List management, will be implemented at the end of April! Be sure to "read all about it!!"
Read more ....

New Remote Roster Administrator Role for RIPPLE
RIPPLE, Canadian Cancer Trials Group's new electronic web-based system for membership accounts and Participant List management, will be implemented at the end of April. This new system requires each Canadian Cancer Trials Group member centre to assign a Remote Roster Administrator Role.
Read more ....

March is Colorectal Cancer Awareness Month
In recognition of Colorectal Cancer Awareness Month, the Canadian Cancer Society and Queen's University are highlighting the Canadian Cancer Trials Group's CHALLENGE trial (aka Canadian Cancer Trials Group CO.21).
Read more ....

Recent Publications
There were four recent publications -- three reporting primary results (Canadian Cancer Trials Group BR.29, Canadian Cancer Trials Group IND.190, and Canadian Cancer Trials Group CXC.1 [GOG 0219]) and the other related Canadian Cancer Trials Group MA.14.
Read more ....

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards -- TIME IS RUNNING OUT!!!
The Canadian Cancer Trials Group's Central Office is seeking nominations for the newly-established Canadian Cancer Trials Group Recognition Awards and the IND Program Awards that will be presented at the upcoming Canadian Cancer Trials Group Spring Meeting of Participants. Deadline for nominations is MARCH 21!!!
Read more ....

Trial Management Group

Recent Trial Activation
Canadian Cancer Trials Group NEC.3 (A 021202) -- An Alliance-led trial entitled Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumours -- was recently activated.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

21 Feb 2014

General

Canadian Cancer Trials Group HD.6 Higlighted by the Canadian Cancer Society
A story highlighting the results of Canadian Cancer Trials Group HD.6 has recently been published in the Canadian Cancer Society's publication "Fighting for Life."
Read more ....

Recent Publication
There was one recent publication investigating the relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuxminab in the Canadian Cancer Trials Group CO.17 trial.
Read more ....

Group Administrators Office

2014 Annual Spring Meeting
The Canadian Cancer Trials Group 2014 Annual Spring Meeting of Participants will be held May 2-4, 2014 at the Eaton Chelsea Hotel in Toronto. Full-funded and non-funded invitations have been sent. Travel and hotel information and a draft overall schedule are now available.
Read more ....

Canadian Cancer Trials Group Recognition Awards
The Canadian Cancer Trials Group's Central Office is seeking nominations for the newly-established Canadian Cancer Trials Group Recognition Awards and the IND Program Awards that will be presented at the upcoming Canadian Cancer Trials Group Spring Meeting of Participants.
Read more ....

GCP and Division 5 Training
The Office of Compliance and Oversight and Group Administrator's Office are currently working on processes for GCP training reciprocity and Health Canada Division 5 training. More information will be provided later this spring.
Read more ....

Participating Centre Agreements Expiring in 2014
In 2014, a number of Canadian Cancer Trials Group's Participating Centre Agreements with its Canadian member centres will be expiring. Staff from the Group Administrator's Office will be contacting those centres next week to begin the process of renewal.
Read more ....

Transitioning to the NCI's NCTN
The US Cooperative Group system is in the process of transitioning to the NCI National Clinical Trials Network (NCTN). We wanted to update our member centres about how these changes will affect them.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Feb 2014

General

CRA Volunteer Needed for Hematology Executive Committee
Canadian Cancer Trials Group is actively seeking a CRA representative to sit on the Hematology Disease Site Committee Executive.
Read more ....

Updates from the CRA Executive Committee
The Canadian Cancer Trials Group's CRA Executive Commmittee announces the appointment of new members to the committee. In addition, it would like to share summary information from the Spring Meeting 2013 session, "What Works: Sharing Member Centres Best Practices".
Read more ....

Recent Publication
There was one recent publication related to Canadian Cancer Trials Group MA.5 and Canadian Cancer Trials Group MA.12 assessing whether alternative methods of measuring tumour size enhance prognostic information beyond TNM staging in women with early stage breast cancer.
Read more ....

Group Administrators Office

Canadian Cancer Trials Group Holiday Closure - Family Day
The Canadian Cancer Trials Group (Central Office) will be closed on Monday, February 17, 2014 to celebrate Family Day.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group BL.12 -- A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen -- was centrally activated January 27, 2014.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 Jan 2014

General

IND Recognition Awards
Once again, the Canadian Cancer Trials Group's Investigational New Drug (IND) Program is requesting nominations for the 2014 IND Program Young Investigator Award.
Read more ....

Group Administrators Office

Canadian Cancer Trials Group Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2014 Annual Spring Meeting of Participants will be held May 2-4, 2014 at the Eaton Chelsea Hotel (formerly The Delta Chelsea Hotel) in Toronto.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group BLC.1 (SWOG 1011) -- a surgical trial evaluating the benefit of standard vs extended lymphadenectomy in muscle-invasive urothelial cancer -- was activated January 15, 2014.
Read more ....

2014 Permanent Trial Closure
The Canadian Cancer Trials Group's Trial Management Group has completed its annual Permanent Trial Closure assessment. A total of 8 trials have been permanently closed, including MA.22, LY.9, BR.29, SC.20, IND.199, IND.200, IND.203 and IND.212.
Read more ....

Trial Closed to Accrual
Canadian Cancer Trials Group SR.6 (SARC021) - A Randomized Phase III, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma - is closed to accrual.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

10 Jan 2014

General

Recent Publications
There were three recent publications -- one related to Canadian Cancer Trials Group MA.12 and the others related to Canadian Cancer Trials Group CO.17.
Read more ....

Primary Results of NCIC SC.20 Published by Lancet Oncology
The primary results of Canadian Cancer Trials Group SC.20, recently published online by Lancet Oncology, show that radiation treatment can help relieve painful bone metastases, even when previous radiation treatment has been given.
Read more ....

Office of Compliance and Oversight

REMINDER: Ethics Contact Email Change - CER@ctg.queensu.ca
Just a reminder that centres should be using the Office of Compliance and Oversight's centralized Ethics email address, CER@ctg.queensu.ca, for all Ethics communication.
Read more ....

CTEP transition of SAE reporting from AdEERS to CTEP-AERS
CTEP has announced that its CTEP-AERS system for SAE reporting is now totally functional and can now be used in place of AdEERS.
Read more ....

Trial Management Group

Trials Closed to Accrual
Three trials were recently closed to accrual -- Canadian Cancer Trials Group EN.7 (PORTEC-3), Canadian Cancer Trials Group IND.207 and Canadian Cancer Trials Group IND.205 Part B.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins